User:Edwinam23/sandbox

The rotavirus is a common cause of diarrhea in infants and young children and a significant public health issue in low and middle-income countries. The first licensed vaccine in the US was the RotaShield in 1998. Unfortunately, it was withdrawn a year later due to an increase in the risk of bowel obstruction after receiving the first dose. In 2006 the two vaccines RotaTeq (RV5) and Rotarix (RV1) were licensed in Europe, the US, and Canada. Financial support was provided to help negotiate lower prices of vaccines to increase accessibility to low and middle-income countries. Diplomatic efforts were proven to take effect as vaccines had been available to low and middle-income countries since 2009, cost-effective in most settings reported in 2019. Over 100 countries have national immunization programs in effect that introduce the vaccine. But only low-income countries benefit from support internationally whereas middle-income countries are not offered this same support since July 2020. The rate of vaccines being more cost-effective is around 90% overall for all countries to use.